Drug
Lenacapavir
Lenacapavir: highest development phase Phase 2/3, developed by Gilead Sciences. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Oral Lenacapavir NCT04150068 | Phase 2/3 | HIV-1-infection |
| Lenacapavir NCT03739866 | Phase 1 | HIV-1 Infection |
Latest
No recent events.
Follow Lenacapavir on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.